Interferon Treatment Improves Survival among Liver Transplant Recipients with Recurrent Hepatitis C
Journal Title: Journal of Surgery - Year 2013, Vol 1, Issue 1
Abstract
Hepatitis C in the liver allograft recipient has an aggressive course. A significant proportion of such recipients develop graft fibrosis and cirrhosis within five years of transplantation. Treatment efficacy with standard or pegylated interferon and ribavirin is suboptimal compared to the immunocompetent individuals. However, the effect of such therapy on graft and patient survival remains unknown. Objectives: To determine the efficacy of interferon based therapies in liver transplantation recipients with recurrent hepatitis C, and to determine the effect of interferon treatment on graft and patient survival. Methods: We retrospectively analyzed 823 hepatitis C patients, who underwent liver transplantation at Thomas E Starzl Transplantation Institute, University of Pittsburgh between January 1992 and April 2006. Two hundred and sixty four patients received either interferon (all kinds) monotherapy, or combination therapy. The primary end point was graft failure and death. Results: Both treated and untreated groups were similar in clinical characteristics at the time of transplantation. In treatment group, 77% received prednisone based immunosuppression as compared to 75% in no treatment group. 57% of patients in treatment group had HCV RNA >1 million units/ml after transplantation. Patients were categorized into four groups; no treatment (n=440), ≤ 24 weeks of treatment (n=38), 25-48 weeks of treatment (n=64) and >48 weeks of treatment (162). Total bilirubin > 2 at 6 and 12 months and an AST/ALT ratio of >1 at 6 month of transplantation are independently associated with poor patient survival. Patients who received treatment for >48 weeks have significantly improved survival independent of sustained viral response (HR 0.33, p=< 0.001). Conclusion: Among liver transplant recipients with recurrent hepatitis C, treatment with any interferon with or without ribavirin for >48 weeks is significantly associated with improved patient survival regardless of viral response. Prospective trials are indicated to confirm these findings.
Authors and Affiliations
Shahid Habib
Keywords
Related Articles
- EP ID EP203756
- DOI 10.13188/2332-4139.1000007
- Views 125
- Downloads 0
Comparison of J-Shaped Incision and Mercedes Incision for Liver Transplantation
Wound-related and incision-related complications such as wound infections and incisional hernias are common after liver transplantation. Advances in surgical, anesthesiological, critical care, and immunological innovatio...
Multistep Progression from Atypical Adenomatous Hyperplasia to Lung Adenocarcinoma: Clinico-Pathologic, Epigenetic and Genetic Aspects
Detection of small peripheral ground-glass opacity nodules has increased due to the advances in imaging modalities and the widespread use of computed tomography screening. Pathologic examination of these nodules revealed...
The Role of Prophylactic Lymph Node Dissection in Patients with Intrahepatic Cholangiocarcinoma
Purpose: We investigated the role of prophylactic lymph node dissection (LND) in patients with intrahepatic cholangiocarcinoma (ICC). Methods: A retrospective analysis was performed evaluating the impact on survival of...
Tubularized Incised Plate (TIP) Repair Improves Outcome of Hypospadias Repair
Aim of the study: To analyze if a change of surgical method affects the complication rate in hypospadias surgery. Methods: Over a period of six years, the Mathieu procedure was replaced by the Tubularized Incised Plate...
Clinical Outcome of Supracricoid Partial Laryngectomy: Experience on 31 Patients
Objective: Supracricoidpartial laryngectomy with Cricohyoidoepiglottopexyor Cricohyoïdopexieis an organ preservation surgery indicated for selected T1 to T3 laryngeal cancers. To evaluate functional and oncological outco...